Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
H3K4me1
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "H3K4me1" in MCE Product Catalog:
Cat. No.: HY-403538
CAS No.: 1358901-59-3
Target:
Research Areas:
iZMYND8-34 is a ZMYND8 inhibitor with an IC50 of 0.66 μM. iZMYND8-34 inhibits the binding of H3K4me1–H3K14ac peptide to the ZMYND8 protein. iZMYND8-34 inhibits ZMYND8’s histone recognition. iZMYND8-34 blocks neuroendocrine prostate cancer development .
Target:
Research Areas:
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC50 of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs .
Target:
Cat. No.: HY-P2255
Target:
Research Areas:
Target:
Research Areas:
LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .
Cat. No.: HY-176283
Research Areas:
Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and LSD1 (IC50 = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells .
Cat. No.: HY-P10819
Target:
Research Areas:
Cat. No.: HY-168086
CAS No.: 2992690-04-5
Target:
Research Areas:
LSD1-IN-35 (Compound Z-1) is a selective LSD1 Inhibitor (IC50: 108 nM). LSD1-IN-35 inhibits the demethylation on H3K4me1/2. LSD1-IN-35 is an immunomodulator. LSD1-IN-35 promotes response of gastric cancer cells to T-cell killing effect by decreasing PD-L1 expression and further attenuates the PD-1/PD-L1 interaction .
Cat. No.: HY-181781
CAS No.: 3104325-26-7
Target:
Research Areas:
LSD1-IN-48 is a tranylcypromine-pyrimidine derivative and selective LSD1 inhibitor with a human IC50 of 7.87 nM. LSD1-IN-48 increases H3K4me1/2 histone methylation levels. LSD1-IN-48 induces apoptosis, upregulates CD86, downregulates SOX2 and CD44, inhibits proliferation in cancer cells. LSD1-IN-48 can be used for the research of acute myeloid leukemia .
Cat. No.: HY-124961
CAS No.: 927019-63-4
Target:
Research Areas:
LSD1-IN-2 is a LSD1 inhibitor with an IC50 of 0.5 μM. LSD1-IN-2 increases the levels of monomethylated and dimethylated histone H3 lysine 4 (H3K4me1/2) in cells. LSD1-IN-2 reactivates epigenetically silenced tumor suppressor genes. LSD1-IN-2 can be used in the research of colon cancer .
Cat. No.: HY-187092
CAS No.: 1423715-30-3
Target:
Research Areas:
LSD1-IN-51 is a selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 8.7 nM. LSD1-IN-51 selectively inhibits H3K4me1/2 demethylation by binding to the FAD domain of LSD1, while disrupting the interaction between LSD1 and multiprotein complexes such as HDAC1/2 and CoREST. LSD1-IN-51 can be used for cancer research .
Cat. No.: HY-184101
Research Areas:
CC-90011-COOH is a LSD1 ligand. CC-90011-COOH serves as a Ligand for Target Protein for PROTAC for the synthesis of LSD1 PROTAC degraders, such as MS9117 (HY-184097). CC-90011-COOH is applicable to the research of acute myeloid leukemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
